Dr. Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and was Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on what provokes relapses and remissions in Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO), and the quest for antigen specific therapy. He is developing a small molecule therapeutic currently in clinical trials for Huntington’s Disease. He was senior author on the 1992 Nature article that led to the drug Tysabri, approved for MS and Crohn’s Disease.

Dr. Steinman graduated from Dartmouth College, Magna Cum Laude in Physics. His MD is from Harvard Medical School. He was a post-doctoral fellow in Chemical Immunology at the Weizmann Institute of Science. After a neurology residency at Stanford University he joined the faculty in 1980. He has received numerous honors, including the John M. Dystel Prize in 2004, the Javits Neuroscience Investigator Award from the NINDS twice, and the Charcot Prize in MS research. Dr. Steinman is a member of the National Academy of Sciences and the National Academy of Medicine. Dr. Steinman holds 41 patents. He cofounded several biotech companies including Neurocrine Biosciences, Bayhill Therapeutics (now Tolerion), Nuon Therapeutics, Transparency Life Sciences and Atreca. He was a Director of Centocor from 1988 until its sale to Johnson and Johnson. He currently serves as a Director of BioAtla.